Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 15/20 | 0.50 |
| ▸ | FABP3 | P05413 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767057 | 0.92 | FABP4 (0.46) | FABP4FABP3MEN1KMT2A | |
| SCHEMBL5770181 | 0.85 | FABP4 (0.48) | FABP4FABP3NOTUM | |
| SCHEMBL5772908 | 0.77 | CCR2 (0.47) | FABP4FABP3NOTUMMEN1KMT2A | |
| SCHEMBL5770046 | 0.76 | PLA2G2A (0.52) | FABP4FABP3 | |
| SCHEMBL5770049 | 0.76 | PLA2G2A (0.42) | FABP4FABP3 | |
| SCHEMBL6393255 | 0.76 | PLA2G2A (0.47) | FABP4FABP3 | |
| SCHEMBL6404040 | 0.74 | PLA2G2A (0.47) | FABP4FABP3 | |
| SCHEMBL6397021 | 0.74 | PLA2G2A (0.47) | FABP4FABP3 | |
| SCHEMBL8180702 | 0.72 | CYP19A1 (0.59) | FABP4FABP3NOTUMMEN1KMT2A | |
| SCHEMBL6397436 | 0.72 | PLA2G2A (0.47) | FABP4FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349836-B1 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6992100-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040092543-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092543-A1 | Novel spla2 inhibitors | PLA2G12A, PLAAT2, SPINT2 | FABP4 261/4885FABP3 131/4885NOTUM 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.